Replies to post #471207 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

As expected, no response to my question regarding whether you realized the 'better performing control arm' from the 2018 results was actually full of DCVax-L crossover patients.

The control arm was 66% "late" DCVax-L and 33% no DCVax-L, This was compared to 100% "early" DCVax-L

Even if you assume "late" is as good as "early", you should still see an advantage for treatment arm. Might lose stat sig because of the confounding, but should still trend right if DCVax-L is such a wonder drug.

But to make matters worse, LL herself says late should not be very effective w/o debulking surgery, and most did not have that.